File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Better survival in female patients with hepatocellular carcinoma: Oral contraceptive pills related?

TitleBetter survival in female patients with hepatocellular carcinoma: Oral contraceptive pills related?
Authors
Issue Date2005
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.com
Citation
Journal Of Clinical Gastroenterology, 2005, v. 39 n. 6, p. 533-539 How to Cite?
AbstractBackground: Hepatocellular carcinoma (HCC) has an indisputable male predominance. "Gender" as an independent prognostic factor for survival is, however, controversial. Goals: Determine the influence of gender on survival in HCC patients, and identify factors that may account for the difference. Methods: A retrospective analysis on a prospectively collected database in a 15-year period, from 1989 to 2003. Results: A total of 3,171 HCC patients were managed in our institution (946 with curative treatment, 1,388 with palliative treatment, and 837 with supportive treatment) and studied. Female patients (n = 520) were 4.3 years older (P = 0.000), had a lower proportion of smokers and drinkers (P = 0.000), and were less likely to be hepatitis B carriers (P = 0.000). There was no difference in Child-Pugh status, tumor size, and the use of different treatments between genders. The overall median survival was 25.7 months longer in females after curative treatment (73.6 vs. 47.9 months; P = 0.012). The survival benefit in female patients was observed in early-stage diseases and persisted when only hepatitis B surface antigen-positive patients were analyzed (96.4 vs. 47.9 months; P = 0.044). With multivariate analysis, gender, indocyanine green test value at 15 minutes, number of tumor nodules, size of tumor, major vascular invasion, invasion of adjacent organs, and tumor rupture were the independent variables for survival. More importantly, in female patients, history of using oral contraceptive was an independent factor with survival benefit (P = 0.004). Conclusion: Gender is an independent variable for survival after curative treatment of HCC. A survival benefit was observed in females. History of using oral contraceptive is associated with a better long-term survival in female patients. Copyright © 2005 by Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/84092
ISSN
2015 Impact Factor: 3.163
2015 SCImago Journal Rankings: 1.274
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, CMen_HK
dc.contributor.authorYong, JLen_HK
dc.contributor.authorChan, AOen_HK
dc.contributor.authorNg, KKen_HK
dc.contributor.authorPoon, RTen_HK
dc.contributor.authorLiu, CLen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T08:48:50Z-
dc.date.available2010-09-06T08:48:50Z-
dc.date.issued2005en_HK
dc.identifier.citationJournal Of Clinical Gastroenterology, 2005, v. 39 n. 6, p. 533-539en_HK
dc.identifier.issn0192-0790en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84092-
dc.description.abstractBackground: Hepatocellular carcinoma (HCC) has an indisputable male predominance. "Gender" as an independent prognostic factor for survival is, however, controversial. Goals: Determine the influence of gender on survival in HCC patients, and identify factors that may account for the difference. Methods: A retrospective analysis on a prospectively collected database in a 15-year period, from 1989 to 2003. Results: A total of 3,171 HCC patients were managed in our institution (946 with curative treatment, 1,388 with palliative treatment, and 837 with supportive treatment) and studied. Female patients (n = 520) were 4.3 years older (P = 0.000), had a lower proportion of smokers and drinkers (P = 0.000), and were less likely to be hepatitis B carriers (P = 0.000). There was no difference in Child-Pugh status, tumor size, and the use of different treatments between genders. The overall median survival was 25.7 months longer in females after curative treatment (73.6 vs. 47.9 months; P = 0.012). The survival benefit in female patients was observed in early-stage diseases and persisted when only hepatitis B surface antigen-positive patients were analyzed (96.4 vs. 47.9 months; P = 0.044). With multivariate analysis, gender, indocyanine green test value at 15 minutes, number of tumor nodules, size of tumor, major vascular invasion, invasion of adjacent organs, and tumor rupture were the independent variables for survival. More importantly, in female patients, history of using oral contraceptive was an independent factor with survival benefit (P = 0.004). Conclusion: Gender is an independent variable for survival after curative treatment of HCC. A survival benefit was observed in females. History of using oral contraceptive is associated with a better long-term survival in female patients. Copyright © 2005 by Lippincott Williams & Wilkins.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.comen_HK
dc.relation.ispartofJournal of Clinical Gastroenterologyen_HK
dc.rightsJournal of Clinical Gastroenterology. Copyright © Lippincott Williams & Wilkins.en_HK
dc.subject.meshCarcinoma, Hepatocellular - mortality - therapyen_HK
dc.subject.meshChi-Square Distributionen_HK
dc.subject.meshContraceptives, Oral - administration & dosageen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHong Kong - epidemiologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLiver Neoplasms - mortality - therapyen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshStatistics, Nonparametricen_HK
dc.subject.meshSurvival Analysisen_HK
dc.titleBetter survival in female patients with hepatocellular carcinoma: Oral contraceptive pills related?en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0192-0790&volume=39&issue=6&spage=533&epage=539&date=2005&atitle=Better+survival+in+female+patients+with+hepatocellular+carcinoma:+oral+contraceptive+pills+related?en_HK
dc.identifier.emailPoon, RT: poontp@hkucc.hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityPoon, RT=rp00446en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/01.mcg.0000165670.25272.46en_HK
dc.identifier.pmid15942442-
dc.identifier.scopuseid_2-s2.0-20844460628en_HK
dc.identifier.hkuros116927en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-20844460628&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume39en_HK
dc.identifier.issue6en_HK
dc.identifier.spage533en_HK
dc.identifier.epage539en_HK
dc.identifier.isiWOS:000229882100013-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLam, CM=7402989820en_HK
dc.identifier.scopusauthoridYong, JL=7102704670en_HK
dc.identifier.scopusauthoridChan, AO=7403167965en_HK
dc.identifier.scopusauthoridNg, KK=35248894000en_HK
dc.identifier.scopusauthoridPoon, RT=7103097223en_HK
dc.identifier.scopusauthoridLiu, CL=7409789712en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats